

Regular Meeting of the

Santa Clara County Health Authority Pharmacy and Therapeutics (P&T) Committee

Thursday, December 16, 2021, 6:00 - 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Via Teleconference

(408) 638-0968

Meeting ID: 879 4364 5193

Passcode: **SCFHP2021**

<https://us06web.zoom.us/j/87943645193>

AGENDA

1. Roll Call / Establish Quorum	Dr. Lin	6:00	5 min
2. Public Comment Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of the public comment period to 30 minutes.	Dr. Lin	6:05	5 min
3. Open Meeting Minutes Review Santa Clara Family Health Plan (SCFHP) 3Q 2021 P&T Open Session Minutes. Possible Action: Approve SCFHP P&T Open Session Minutes	Dr. Lin	6:10	2 min
4. Standing Agenda Items			
a. Chief Medical Officer Health Plan Updates	Dr. Nakahira	6:12	5 min
b. Grievance & Appeals 2Q 2021 and 3Q 2021 Pharmacy Reports	Mr. Oliveira	6:17	3 min
c. Medi-Cal Rx Update	Dr. Huynh	6:20	2 min
d. Policy Review – PH.12 Drug Management Program	Dr. Huynh	6:22	2 min
e. Plan/Global Medi-Cal Drug Use Review	Dr. Otomo	6:24	2 min
i. Drug Utilization Evaluation Update			
f. Emergency Supply Report – 3Q 2020, 4Q 2020	Dr. Nguyen	6:26	2 min
Adjourn to Closed Session			
<i>Pursuant to Welfare and Institutions Code Section 14087.36 (w)</i>			
5. Closed Meeting Minutes Review SCFHP 3Q 2021 P&T Closed Session Minutes. Possible Action: Approve SCFHP P&T Closed Session Minutes	Dr. Lin	6:28	2 min
6. Metrics & Financial Updates			
a. Membership Report	Dr. Nakahira	6:30	1 min
b. Pharmacy Dashboard	Dr. Otomo	6:31	2 min
c. Drug Utilization & Spend – 3Q 2021	Dr. McCarty	6:33	5 min

7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria	Dr. McCarty	6:38	3 min
<ul style="list-style-type: none"> a. Pharmacy Benefit Manager 3Q 2021 P&T Minutes b. Pharmacy Benefit Manager 4Q 2021 P&T Part D Actions Possible Action: Approve MedImpact Minutes & Actions 			
<ul style="list-style-type: none"> c. 2022 Medical Benefit Drug Prior Authorization Grid Possible Action: Approve 2022 Medical Benefit Drug Prior Authorization Grid for Cal MediConnect 	Dr. Otomo	6:41	2 min
8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal Formulary & Prior Authorization Criteria			
<ul style="list-style-type: none"> a. Old Business/Follow-Up 			
<ul style="list-style-type: none"> i. PCSK9 Inhibitors 	Dr. McCarty	6:43	2 min
<ul style="list-style-type: none"> ii. Trijardy XR 	Dr. Le	6:45	2 min
<ul style="list-style-type: none"> b. Formulary Modifications Possible Action: Approve Formulary Addition and Modification Recommendations 	Dr. Otomo	6:47	2 min
<ul style="list-style-type: none"> c. Fee-for-Service Contract Drug List Comparability Possible Action: Approve CDL Comparability Formulary Recommendations 	Dr. McCarty	6:49	5 min
<ul style="list-style-type: none"> d. 2022 Medical Benefit Drug Prior Authorization Grid Possible Action: Approve 2022 Medical Benefit Drug Prior Authorization Grid for Medi-Cal 	Dr. Otomo	6:54	1 min
<ul style="list-style-type: none"> e. Prior Authorization Criteria 	Dr. Nguyen	6:55	5 min
<ul style="list-style-type: none"> i. <u>New/Revised Criteria</u> 			
<ul style="list-style-type: none"> 1. Stromectol 			
<ul style="list-style-type: none"> 2. Zeposia 			
<ul style="list-style-type: none"> ii. <u>Annual Review</u> 			
<ul style="list-style-type: none"> 1. Non-formulary 			
<ul style="list-style-type: none"> 2. Norditropin Flexpro 			
<ul style="list-style-type: none"> 3. Protopic ointment 			
<ul style="list-style-type: none"> 4. Zarxio 			
<ul style="list-style-type: none"> Possible Action: Approve PA Criteria Recommendations 			
9. New Drugs and Class Review	Dr. McCarty	7:00	55 min
<ul style="list-style-type: none"> a. COVID-19 Updates 			
<ul style="list-style-type: none"> b. Inhaled tobramycin 			
<ul style="list-style-type: none"> c. Difucid 			
<ul style="list-style-type: none"> d. New and Expanded Indications – Nucala, Fasenra, Xywav 			
<ul style="list-style-type: none"> e. New Entities, Derivatives & Formulations – Tyrvaya, Myrbetriq granules, Trudhesa 			
<ul style="list-style-type: none"> f. Informational only: 			
<ul style="list-style-type: none"> i. Myelofibrosis – pacritinib 			
<ul style="list-style-type: none"> ii. Presbyopia – presbysol 			
<ul style="list-style-type: none"> iii. Acute agitation – dexmedetomidine 			
<ul style="list-style-type: none"> iv. Pulmonary hypertension 			
<ul style="list-style-type: none"> v. Weight loss agents 			
<ul style="list-style-type: none"> vi. Continuous glucose monitors 			
<ul style="list-style-type: none"> vii. Drugs: Pennsaid, Santyl, Kuvan, Upneeq, Cosentyx, omidenepag isopropyl, maribavir, daridorexant, tezepelumab 			
<ul style="list-style-type: none"> Possible Action: Approve New Drug and Class 			
<ul style="list-style-type: none"> Recommendations 			

Reconvene in Open Session

10. Discussion Items

a. New and Generic Pipeline

Dr. McCarty

7:55

5 min

11. Adjournment

Next meeting Thursday March 17, 2022

Dr. Lin

8:00

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The Committee may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Ave, San Jose, CA 95119.

This agenda and meeting documents are available at www.scfhp.com